Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31115852 | 0.86 | FFAR1 (0.34) | MAPK1P2RX7FFAR1 | |
| SCHEMBL38661230 | 0.85 | MAPK1 (0.35) | MAPK1P2RX7FFAR1 | |
| SCHEMBL24009400 | 0.85 | MAPK1 (0.35) | MAPK1P2RX7FFAR1 | |
| SCHEMBL24010961 | 0.85 | MAPK1 (0.35) | MAPK1P2RX7FFAR1 | |
| SCHEMBL31313781 | 0.84 | FFAR1 (0.33) | MAPK1FFAR1 | |
| SCHEMBL31115836 | 0.83 | MAPK1 (0.34) | MAPK1P2RX7FFAR1 | |
| SCHEMBL27166611 | 0.83 | MAPK1 (0.34) | MAPK1P2RX7FFAR1 | |
| SCHEMBL31313944 | 0.83 | MAPK1 (0.36) | MAPK1P2RX7FFAR1 | |
| SCHEMBL27166678 | 0.83 | FFAR1 (0.34) | MAPK1P2RX7FFAR1 | |
| SCHEMBL26988775 | 0.82 | FFAR1 (0.33) | MAPK1P2RX7FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720062-A1 | PYRIDO[3,4-D]PYRIMIDIN-4-ONE AND PYRIMIDO[5,4-D]PYRIMIDIN-4-ONE DERIVATIVES AS TREM2 AGONISTS FOR THE TREATMENT OF PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4551575-A2 | TREM2 MODULATORS | Muna Therapeutics ApS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024246019-A1 | PYRIDO[3,4-D]PYRIMIDIN-4-ONE AND PYRIMIDO[5,4-D]PYRIMIDIN-4-ONE DERIVATIVES AS TREM2 AGONISTS FOR THE TREATMENT OF PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-05 | — | — | WO | disclosed |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-06 | — | — | US | disclosed |
| EP-4334295-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Vigil Neuoscience, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11884675-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2024008722-A2 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024008722-A2 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2024-01-11 | — | — | WO | disclosed |
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | AMGEN INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | AMGEN INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230144581-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230144581-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11608344-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4146222-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Amgen Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146220-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Amgen Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2022236272-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2021226135-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | MAPK1 1254/4885P2RX7 67/4885FFAR1 133/4885 |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | MAPK1 1254/4885P2RX7 67/4885FFAR1 133/4885 |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | MAPK1 1254/4885P2RX7 67/4885FFAR1 133/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | MAPK1 1254/4885P2RX7 67/4885FFAR1 133/4885 |
| US-11608344-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | MAPK1 1254/4885P2RX7 67/4885FFAR1 133/4885 |
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | MSR1, FPR2, CD14 | MAPK1 1205/4885P2RX7 82/4885FFAR1 148/4885 |
| US-20230144581-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | MAPK1 1205/4885P2RX7 82/4885FFAR1 148/4885 |
| US-11884675-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | MAPK1 1254/4885P2RX7 67/4885FFAR1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.